Cathie Wood’s ARK Invest Doubles Down on CRISPR Therapeutics Amid Market Dip

Cathie Wood's ARK Invest has once again demonstrated its commitment to the genomic revolution by purchasing shares of CRISPR Therapeutics (CRSP) during a recent price decline. This move is characteristic of Wood’s investment philosophy, which prioritizes long-term disruptive potential over short-term market volatility. CRISPR Therapeutics, a leader in the CRISPR-Cas9 space, remains a cornerstone of ARK’s flagship Innovation ETF (ARKK) and Genomic Revolution ETF (ARKG), reflecting a belief that gene editing is a generational investment opportunity.

The "dip" in CRISPR’s stock price comes at a critical juncture for the company. Following the historic FDA approval of Casgevy—the first-ever CRISPR-based gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia—the market has shifted its focus from regulatory milestones to commercial execution. The high cost of the therapy, priced at approximately $2.2 million per patient, and the complex infrastructure required for administration have led to a "show-me" period for investors. This transition from clinical-stage biotech to commercial-stage pharmaceutical entity often involves a period of valuation adjustment as investors wait for tangible revenue data, a window that Wood is now exploiting to lower her average cost basis.

“

Cathie Wood's ARK Invest has once again demonstrated its commitment to the genomic revolution by purchasing shares of CRISPR Therapeutics (CRSP) during a recent price decline.

Wood’s purchase serves as a significant vote of confidence for the broader gene-editing sector, which has faced headwinds from high interest rates and a cautious funding environment. By increasing her stake, Wood is betting that the long-term value of CRISPR’s platform—which includes a pipeline targeting oncology, autoimmune diseases, and cardiovascular health—far outweighs the current commercialization hurdles of its lead product. This move may also signal to retail investors that the current valuation offers an attractive entry point for a company with a first-mover advantage in a multi-billion dollar market. The competitive landscape for CRISPR Therapeutics is also evolving rapidly; while CRSP holds the first-mover advantage with Casgevy, peers like Intellia Therapeutics and Beam Therapeutics are advancing their own platforms, including in vivo editing and base editing technologies. Wood’s decision to double down on CRSP suggests a belief that the company’s established regulatory pathway and partnership with Vertex Pharmaceuticals provide a more stable foundation compared to its earlier-stage rivals.